



Evaluation of Dimpa Injectable Contraceptive Network in India

Dr. Vivek Sharma, Moni Sagar and Arunesh Singh Abt Associates 14 November 2013

Structure

- Genesis of the Dimpa program
- Program Objective
- Key interventions
- Methods of evaluation
- Results
- Implications
- Lessons learned

Genesis of the Dimpa program

- DMPA a 3-monthly injectable contraceptive cleared for marketing by Drug Controller General of India in 1993
- The product faced hostile environment
 - Misinformed opposition from women's rights group questioning safety and quality of provision
 - Triggered Govt. towards non acceptance of DMPA as a part of the basket of methods in the FP program
 - Low awareness among clients and health care providers
- Continuing USAID's commitment to expanding contraceptive options available to couples in India:
 - Decision to support introduction of DMPA through the private sector
 - Project to demonstrate the feasibility of providing DMPA and consumer acceptance; build evidence to support inclusion of DMPA in the national program

Objective of the Dimpa program

Increase overall use of modern reversible contraceptive methods by introducing DMPA to the method mix of contraceptive choice through a network of qualified private providers

Key interventions

Creating & Capacity Building of Network of Private Qualified Providers

<u>The Dimpa Clinic</u> Mostly Ob-Gyn, female GPs

Demand Generation through Mass Media & Outreach



Building Partnerships with Commercial & Social Marketing Agencies

From 3 towns, 105 clinics, by 2003 to 45 towns, 1200 clinics, by 2009

Developing & Implementing Dimpa Telephone Helpline

Ob-Gyn: Obstetrician / Gynecologist , GP: General Physicians

Methods of evaluation

Quantitative studies

- Networked providers
 - Baseline: 159 providers, August 2009
 - Endline : 160 providers , October 2011
- Currently married women aged 15-49 & not-sterilized
 - Baseline: 1646 women, April 2009
 - Endline : 1760 women , December 2011
- Sales reports of Dimpa network clinic & chemist

• Helpline data :

- Post user support: Continuation rate among users registered at Helpline, number of users who received services
- Inbound call: Profile of callers, information sought on type of FP methods





Results

Significant increase in % of providers adhering to prescribed QoC standards



QoC standards : Discussed DMPA and at least one other FP method spontaneously and screen client appropriately (menstrual history taken and age of the youngest child and currently breastfeeding was asked)

*: Significantly (p<0.05) different from baseline

N (2009)=159, N (2011)=160

% of providers discussing specific aspects of DMPA is high $^{\rm b}$



*: Significantly (p<0.05) different from baseline b: Significantly (p<0.05) different from the benchmark

N (2009) =159 N (2011)=160

Intention to use, current use and ever use of DMPA among currently married women



*: Significantly (p=<0.05) different from baseline (@: Fisher exact test)

N (2009) =1646

N (2011)=1760

Contribution of program activities

S.No.	Activities		Baseline	Not exposed (Endline)	Exposed (Endline)
1	Ever use of injectable contraceptive (IC)		1.0%	1.1%	<u>3.9</u> %*
2	Aware of IC		74.0%	67.7*	<u>80.6</u> **
3	Know IC for 3 months		26.4	21.5*	<u>50.0</u> *
4	Aware of a clinic where DMPA is available		9.1%	15.3%	<u>29.9</u> *
5	Intend to use injectable in near future		1.5%	1.7%	<u>6.6%</u> *
Evidence of Contribution					

*: Significantly (p=<0.05) different from baseline **: Significantly (p=<0.10) different from baseline Underline: Significantly different from not exposed @: Measured in the scale of 1-10

N:Baseline=1646,Not exposed=1538 Exposed=223 Pa

Sales from network clinics and trained chemists counters grew approx. 70% year-on-year basis*



Telephone-based support to DMPA users increased continuation of the second injection*

Group 1: First time users who did <u>**not**</u> receive any calls

Group 2 (one call) : Received a reminder call two weeks before the due date of the next injection

Group 3 (two calls): Received, in addition, a counseling call one month after their injection

Group 4 (three calls): Received, in addition, a reassurance call one week after their injection

Figure 1: Reported having taken Second Injection



* indicated significantly different from Group 1 (p≤0.05) # indicated significantly different from Group 2 (p≤0.05)

*Results from a pilot test





Program implications and lessons learned

Program implications

- DMPA is at the threshold of being a widely accepted method
- Significant increase in use of DMPA among currently married women aged 15-49 years *
 - Large network of providers offering DMPA with high QoC (improved from 51% to 71%)**
 - No backlash from activists in spite of national mass media advertising
- Market catalyzed
 - Increased number of marketers, one to five
 - Reduced price *from \$4-6 per vial to \$1-2 per vial*
- Increased donor interest in supporting DMPA Gates, Packard in India

Lessons Learned (1/2)

- The 'network' approach vs. training

 The Network acts as a support community, important source of reassurance & confidence
- Follow-on training & support provides tangible difference in provider performance
- Once network is established, it requires minimal support for providing quality of services
- Shifting counseling task from doctor to paramedics can better address missed opportunities

Lessons Learned (1/2)

• It is more appropriate to position FP networks as a way to increase client satisfaction, not just increased client flow

- ICT interventions can help improve continuation rates
 - Helpline is a good mechanism to design such interventions around as it offers anonymity and efficiency
 - Timely collection and quality of data is important for success of an intervention for improving continuation rates





Thank You

Contact Details:

Vivek Sharma, Abt Associates vivek@abtinidia.net